European Lung Cancer Congress 2019: A Multidisciplinary Approach to Fight Lung Cancer
Participants from across the world will meet in Geneva to learn about and discuss the latest research in the field of lung cancer.
ESMO Media Releases
Researchers Develop New Method to Detect Cancerous DNA in Lung Cancer Patients’ Blood: An Advance in Liquid Biopsies
A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from lung cancer patients with a high degree of accuracy.
Françoise Mornex is First Female Recipient of Heine H. Hansen Award
Françoise Mornex is first female recipient of Heine H. Hansen Award
Rare Cancers a Growing Focus of Early-stage Clinical Trials
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2019
TAT International Congress 2019: the home of phase I oncology
The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019
Cancer Drug Development Award Given to Geoffrey Shapiro
The TAT 2019 Honorary Award for cancer drug development has been given to Dr Geoffrey Shapiro for his leadership in developmental therapeutics, particularly in solid tumours
Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques
Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.
ESMO Immuno-Oncology Congress Showcases New Technologies Set to Improve Cancer Treatment
New technologies in immuno-oncology that are set to benefit many more patients with cancer are being showcased at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland
Death Rates from Cancer will Fall in Australasian Countries and Russia in 2018: Researchers Call for Urgent Measures on Tobacco control
Researchers predict that death rates from cancer will fall in 2018 in Australasian countries and in Russia. However, a greater proportion of the population will die in Russia from the disease than in any of the other countries, mainly because of the large numbers of men who still smoke.
ESMO Immuno-Oncology Congress: Where the Community of Stakeholders Meets
ESMO is pleased to announce the ESMO Immuno-Oncology 2018 Congress, a dedicated platform in Europe to keep professionals up to date with the most recent and significant developments in this rapidly evolving field.
Rare Cancers Asia: Building Bridges to Improve Patient Care
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients – challenges which are best addressed through collaboration in international networks.